Stock AMPH AMPHASTAR PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Amphastar Pharmaceuticals, Inc.

Equities

AMPH

US03209R1032

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
43.46 USD +3.70% Intraday chart for Amphastar Pharmaceuticals, Inc. +2.40% -29.73%
May. 22 Sector Update: Health Care Stocks Slightly Higher Late Afternoon MT
May. 22 Sector Update: Health Care Stocks Advance Wednesday Afternoon MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Slightly Higher Late Afternoon
MT
Sector Update: Health Care Stocks Advance Wednesday Afternoon
MT
Amphastar Pharmaceuticals Gains US FDA Approval for Generic Bronchospasm Drug
MT
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 EPS $1.04, vs. Street Est of $0.79
MT
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 Revenue $171.8M, vs. Street Est of $174.7M
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
MT
Amphastar Pharmaceuticals Q4 Adjusted Earnings, Revenue Rise
MT
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Posts Q4 EPS $0.88, vs. Street Est of $0.91
MT
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q4 Revenue $178.1M, vs. Street Est of $173.3M
MT
High-dose opioid reversal spray no better than lower dose in field, US study finds
RE
Amphastar Pharmaceuticals Q3 Adjusted Non-GAAP Earnings, Revenue Rise
MT
Tranche Update on Amphastar Pharmaceuticals, Inc.'s Equity Buyback Plan announced on November 8, 2016.
CI
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Posts Q3 EPS $1.15, vs. Street Est of $0.69
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMPH Stock
  4. News Amphastar Pharmaceuticals, Inc.
  5. Highlights